Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImplanetIMPZY 29 Days Payable is 668.00 as of Dec. 2025, which is 107% above its 10-year median of 323.05. GuruFocus rates IMPZY with a GF Score™ of 29/100 and a GF Value™ of $0.03. The stock has 4 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Implanet ranks better than 93.95% on this metric.
Implanet's average Accounts Payable for the
six
months ended in Dec. 2025 was $12.09 Mil. Implanet's Cost of Goods Sold for the
six
months ended in Dec. 2025 was $3.30 Mil.
Hence, Implanet's Days Payable for the
six
months ended in Dec. 2025 was 668.00.
The historical rank and industry rank for Implanet's Days Payable or its related term are showing as below:
IMPZY'
s Days Payable Range Over the Past 10 Years
Min: 204.2 Med: 323.05 Max: 592.02
Current: 592.02
During the past 13 years, Implanet's highest Days Payable was 592.02. The lowest was 204.20. And the median was 323.05.
IMPZY's Days Payable is ranked better than 93.95% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs IMPZY: 592.02
Implanet's Days Payable
increased
from Dec. 2024 (365.44) to Dec. 2025 (668.00).
It may suggest that Implanetdelayed paying its suppliers.
The historical data trend for Implanet's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Implanet's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Implanet Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Implanet's Days Payable distribution charts can be found below:
* The bar in red indicates where Implanet's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Implanet's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Implanet (IMPZY) has a Days Payable of 668.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Implanet and its competitors. This is 107% above median its historical median of 323.05. Over the past decade, Implanet's Days Payable has ranged from 204.20 to 592.02. According to the industry distribution chart, Implanet ranks #48 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 6%.
Is Implanet's Days Payable too high?
Implanet's current Days Payable of 668.00 is 107% above median its 10-year median of 323.05. Over the past 10 years, this metric has ranged from a low of 204.20 to a high of 592.02. The Medical Devices & Instruments industry median Days Payable is 67.97. Implanet's value of 668.00 is 882.8% above this industry median. Based on the distribution chart, Implanet ranks #48 out of 794 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Implanet has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Implanet's Days Payable compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Implanet ranks #48 out of 794 companies for Days Payable. This places Implanet in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.97. Implanet's value of 668.00 is 882.8% above this benchmark. Historically, Implanet's own Days Payable has ranged from 204.20 to 592.02 over the past decade. While the company's 10-year median is 323.05 vs. the industry median of 67.97, Implanet has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Implanet's current Days Payable of 668.00 is 882.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Implanet and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Implanet's current Days Payable is 668.00, which is 107% above median its own 10-year median of 323.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Implanet stock overvalued right now?
Implanet (IMPZY) has a current Days Payable of 668.00. The stock's GF Value™ is $0.03, compared to a current price of $0.08 — trading 166.7% above its estimated fair value. The current Days Payable is 668.00, which is 107% above median its 10-year median of 323.05 and 882.8% above the Medical Devices & Instruments industry median of 67.97. Implanet's overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Implanet (IMPZY), the current Days Payable is 668.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Implanet (IMPZY) Overvalued in 2026?
Based on GuruFocus' analysis, Implanet stock appears to be overvalued.
The current stock price of $0.08 is trading 166.7% above its estimated GF Value™ of $0.03.
Key valuation signals for IMPZY:
Days Payable: 668.00 (107% above median its 10-year median of 323.05)
GF Value™: $0.03 vs. price of $0.08 (166.7% above fair value)
Industry Position: 882.8% above the Medical Devices & Instruments median (#48 of 794)
No single metric tells the full story. See the IMPZY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Implanet SA designs produce and sell medical implants and devices used in orthopedic surgery. Its products include prosthetic knees, spinal bracing systems, intersomatic cages, pins, suture threads, screws, and anchors. The company operates in a single segment - the commercialization of orthopedic implants. It derives Majority of its geographical revenue from France.
29GF Score
Get the complete analysis for IMPZY
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMPZY has been successfully added to your 
